Table 4 Association between PDGFRA mutational status and clinicopathological parameters, PDGFRα expression and RAS mutational status
Tissue samples (N = 55 CRC) | PDGFRA intron 17–18 | PDGFRA exon 18 | PDGFRA intron 18–19 | |||
|---|---|---|---|---|---|---|
Present | P-value | Present | P-value | Present | P-value | |
Age (years) | 0.239 | 0.5 | 0.643 | |||
< 50 years | 7 (70%) | 4 (40%) | 0 (0%) | |||
≥ 50 years | 21 (51.2%) | 19 (46.3%) | 2 (4.9%) | |||
Gender | 0.43 | 0.55 | 0.599 | |||
Male | 17 (48.6%) | 15 (42.9%) | 1 (2.9%) | |||
Female | 11 (55%) | 9 (45%) | 1 (5%) | |||
Location | 0.119 | 0.083 | 0.339 | |||
Colon | 25 (56.8%) | 22 (50%) | 1 (2.3%) | |||
Rectum | 3 (30%) | 2 (20%) | 1 (10%) | |||
Diameter of tumor | 0.521 | 0.258 | 0.635 | |||
≤ 5 cm | 16 (51.6%) | 15 (48.4%) | 1 (3.2%) | |||
> 5 cm | 11 (55%) | 7 (35%) | 1 (5%) | |||
Invasion of tumor | 0.228 | 0.957 | 0.952 | |||
T2 | 2 (100%) | 1 (50%) | 0 (0%) | |||
T3 | 16 (55.2%) | 13 (44.8%) | 1 (3.4%) | |||
T4 | 10 (41.7%) | 10 (41.7%) | 1 (4.2%) | |||
Lymph node metastasis | 0.077 | 0.924 | 0.125 | |||
N0 | 14 (70%) | 9 (45%) | 0 (0%) | |||
N1 | 6 (33.3%) | 7 (38.9%) | 2 (11.1%) | |||
N2 | 8 (50%) | 7 (43.8%) | 0 (0%) | |||
Histological gradation | 0.283 | 0.871 | 0.035 | |||
Well differentiated | 9 (69.2%) | 5 (38.5%) | 2 (15.4%) | |||
Moderately differentiated | 16 (47.1%) | 15 (44.1%) | 0 (0%) | |||
Poorly differentiated | 3 (37.5%) | 4 (50%) | 0 (0% | |||
PDGFRα expression | 0.089 | 0.024 | 0.103 | |||
Low | 16 (43.2%) | 4 (22.2%) | 2 (11.1%) | |||
High | 12 (66.7%) | 20 (54.1%) | 0 (0%) | |||
RAS status | 0.333 | 0.08 | 0.666 | |||
Wild type | 15 (46.9%) | 17 (53.1%) | 1 (3.1%) | |||
Mutated | 13 (56.5%) | 7 (30.4%) | 1 (4.3%) | |||